Dr. Lawrence Fong is the co-leader of the Cancer Immunotherapy Program and the Efim Guzik Distinguished Professor in Cancer Biology at the University of California, San Francisco (UCSF) Comprehensive Cancer Center.
Dr. Fong is experienced in research and clinical studies with the dendritic cell immunotherapy vaccine sipuleucel-T (Provenge) as well as the anti-CTLA-4 checkpoint immunotherapy ipilimumab. Currently, his lab investigates immunotherapies including checkpoint inhibitors and vaccines for several cancer types, and is focused on developing improved biomarkers for the clinic.
Dr. Fong is a member of CRI’s Clinical Leadership Committee.
Today’s new immunotherapies are changing the paradigm for how we treat patients with cancer.
Let's spread the word about Immunotherapy! Click to share this page with your community.